Corcept Therapeutics Inc
0 products tracked · names used in filings: Corcept Therapeutics Inc
Upcoming milestones
relacorilant: PDUFA target action date (Cushing's syndrome)
Corcept Therapeutics Inc (CORT); relacorilant; NDA; status: set; "…Relacorilant for patients with Cushing’s syndrome – Resubmitted New Drug Application Prescription Drug User Fee Act (PDUFA) date of December 17, 2026 “The ADA and EASD consensus statement is an important advance for the many patients whose difficult-to-control hyperglycemia is a manifestation of undiagnosed…"; filed 2026-11-03 · source
Recent milestones
No recent milestones.
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.